Phaseline

Companies › Arialys Australia

Arialys Australia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ART5803
Monovalent antibody that binds to the NTD of NMDAR NR1 subunit and blocks pathogenic anti-
GRIN1Phase 2Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07093333ART5803Phase 2Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)PsychiatryNov 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GRIN1 (1)

Companies with the same targets

Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Johnson & Johnson (Janssen) atai Therapeutics

Companies built like this

atai Therapeutics SyneuRx International (Taiwan) Syndeio Biosciences NeuroRx Bazelet Nehushtan

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.